Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share

Despite declining Eylea sales, Regeneron's strong performance is driven by Dupixent, a blockbuster drug developed with Sanofi that generated $6 billion in global sales with 38% year-over-year growth. The company's Q2 revenue grew 17% to $4.3 billion, with Dupixent collaboration revenue jumping 51%. While Dupixent faces biosimilar competition in the early 2030s, Regeneron plans to defend its market position through improved formulations, pipeline replacements, and promising candidates like olatorepatide in the weight-loss market.